Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 in Advanced Solid Tumors
NCT06233292Phase 2Completed
- Sponsor
- Zelgen
- Start
- Jun 2022
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in solid tumor, sponsored by Zelgen. Started Jun 2022; status: completed.
02
Drugs
nilvanstomig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06233292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233292.